- Home
- BTM vs AARD Comparison
BTM vs AARD Comparison
Compare BTM & AARD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | BTM | AARD |
|---|---|---|
| Founded | 2016 | 2017 |
| Country | United States | United States |
| Employees | 135 | 40 |
| Industry | Finance: Consumer Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 77.1M | 85.7M |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | BTM | AARD |
|---|---|---|
| Price | $5.97 | $5.45 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 2 | 9 |
| Target Price | $4.10 | ★ $15.29 |
| AVG Volume (30 Days) | ★ 693.4K | 173.8K |
| Earning Date | 05-14-2026 | 05-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $7.33 | N/A |
| P/E Ratio | $3.52 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.76 | $3.35 |
| 52 Week High | $8.30 | $17.94 |
Technical Indicators
Market Signals| Indicator | BTM | AARD |
|---|---|---|
| Relative Strength Index (RSI) | 61.09 | 54.67 |
| Support Level | $3.72 | $4.74 |
| Resistance Level | $6.58 | $6.01 |
| Average True Range (ATR) | 1.13 | 0.37 |
| MACD | 0.25 | 0.26 |
| Stochastic Oscillator | 60.68 | 85.36 |
Price Performance
Historical ComparisonAbout BTM Bitcoin Depot Inc.
Bitcoin Depot Inc owns and operates the widest network of BTMs across North America where customers can buy and sell Bitcoin. Bitcoin Depot helps power the digital economy for users of cash. It has locations across the U.S. and Canada at, among others, the following types of retailers: Convenience Stores and Gas Station Chains, Pharmacies and Grocers and Mall Operators.
About AARD Aardvark Therapeutics Inc.
Aardvark Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing novel, small-molecule therapeutics to activate innate homeostatic pathways for the treatment of metabolic diseases. It is focused on on developing selective compounds, targeting Bitter Taste Receptors (TAS2Rs) for hunger-associated conditions. Its product candidate, ARD-101, is an oral gut-restricted small-molecule agonist of certain TAS2Rs expressed in the gut lumen for which have initiated a Phase 3 clinical trial for hyperphagia associated with PWS.